{
    "nctId": "NCT01806259",
    "briefTitle": "Ketorolac in Breast Cancer Surgery",
    "officialTitle": "Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.",
    "overallStatus": "COMPLETED",
    "conditions": "Curative Breast Cancer Surgery, Inflammatory Positive/Negative Status, Pre Surgical Incision Administration",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 203,
    "primaryOutcomeMeasure": "Recurrence-free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\nWritten informed Consent age : 18-85 years weight: 50-100 kg Neutrophils / Lymphocytes ratio \\>4 and/or \"triple negative\" histological status and/or Positive lymph nodes\n\nExclusion Criteria:\n\nPrevious cancer (behalf of basocellular skin cancer and in situ uterine cervix cancer) Non compliance or refusal of the protocol Positive Pregnancy test Childbearing or breastfeeding mothers Contra-indication for NSAIDs NSAIDs intake in the 5 days before randomisation NSAIDs use planned in the 30 days after randomisation Non curative surgery (T4 or M1 tumor classification )",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}